en · de · es · fr · pt
cjc-1295-notes.peptides5388.com › Topic › Molecular Background And Naming — Research Overview

Molecular Background And Naming — Research Overview

By Editorial Desk · published 2026-03-14 · last reviewed 2026-04-28 · Topic

drug affinity complex raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

Reviewed 2026-04-28. Anything still debated is marked as such rather than presented as settled.

Molecular Background and Naming

Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.

The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.

CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.

Receptor Action and Clearance

Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.

Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.

Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.

Cjc-1295 at a glance

PropertyValueNotes
Molecular weight (no linker)~3.37 kDaCalculated from peptide sequence
Molecular weight (with linker)~3.65 kDaIncludes albumin-binding moiety
AppearanceWhite to off-white powderTypically lyophilized
SolubilitySoluble in waterAlso dissolves in aqueous buffers
Common synonymsModified GRF(1-29), DAC:GRFUsage varies by source

Receptor Action and Pharmacokinetics

CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.

The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.

Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.

Related pages on this site

Handling, Stability and Analysis

Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.

Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.

Mechanism and Pharmacokinetics

Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.

The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.

Further detail

== Further reading == Kropotkin, Peter Alexeivitch; Bealby, John Thomas (1911). "Don Cossacks, Territory of the" . Encyclopædia Britannica. Vol. 8 (11th ed.). p. 412. Peter Holquist, "'Conduct Merciless Mass Terror': Decossackization on the Don, 1919," Cahiers du Monde russe, vol. 38, no. 1/2(Jan.-June 1997), pp. 127–162. In JSTOR Noël Bonneuil, Elena Fursa. 2020. "Nuptiality to regulate the commons? The case of the Don Cossacks (South Russia), 1867–1916." Oxford Economic Papers

Corals predominantly reproduce sexually. About 25% of hermatypic corals (reef-building stony corals) form single-sex (gonochoristic) colonies, while the rest are hermaphroditic. It is estimated more than 67% of coral are simultaneous hermaphrodites.

) to identify patterns such as sudden jumps or drops in stream power, these features can help identify locations where the local terrain controls the flow or widens out as well as areas prone to erosion.

Sources: en.wikipedia.org

Background from the literature

The first Pretzel Time store opened in Trumbull, Connecticut. The company was originally incorporated as Mr. Pretzel Inc. in 1991, but quickly changed its name to Pretzel Time by the time it became a popularly franchised mall-based store in the Northeast. In 1999, Mrs. Fields Famous Brands purchased Pretzelmaker. Later it sold the brands to NexCen in 2007 in a combined transaction total of $29.7 million. In 1996, Mrs. Fields had acquired the now-defunct Hot Sam which it merged with Pretzelmaker in 2005. Global Franchise Group (GFG) purchased NexCen Franchise Management in 2010, and merged Pretzel Time and Pretzelmaker into one brand as Pretzelmaker. Pretzelmaker today is the second largest retailer of freshly baked, hand rolled and twisted pretzels. On June 28, 2021, Global Franchise Group announced that it would be acquired by FAT Brands, owners of Fatburger and Johnny Rockets. The acquisition was completed on July 22. On January 26, 2026, parent company FAT Brands filed for Chapter 11 bankruptcy protection in an effort to shed billions of dollars in debt. The company listed assets and liabilities between $1 billion and $10 billion. After receiving court approval for the sale of its assets, FBG Bid Co. officially acquired the remaining assets from FAT Brands for $595 million on June 18, 2026, including Pretzelmaker.

== Manufacture == Banana powder is formed by using banana pulp, which is mechanically chopped and then processed with hydraulic shear using a colloid mill, turning it into a paste. Sodium metabisulfite is then used to brighten the yellow color of the paste. The paste is then dried by either spray- or drum-drying, although the latter is more common, because none of the paste is lost while drying. Drum-drying also produces about 2% more powder and dries it more thoroughly. Regardless of the drying process, banana powder can generally only stay fresh on the shelf for about a year.

===== MeSH D08.811.464.259 – carbon-nitrogen ligases (EC 6.3) ===== MeSH D08.811.464.259.100 – adenylosuccinate synthase MeSH D08.811.464.259.200 – amide synthases MeSH D08.811.464.259.200.200 – aspartate-ammonia ligase MeSH D08.811.464.259.200.600 – glutamate-ammonia ligase MeSH D08.811.464.259.300 – argininosuccinate synthase MeSH D08.811.464.259.350 – carbamoyl-phosphate synthase (ammonia) MeSH D08.811.464.259.400 – carbon-nitrogen ligases with glutamine as amide-n-donor MeSH D08.811.464.259.400.300 – carbamoyl-phosphate synthase (glutamine-hydrolyzing) MeSH D08.811.464.259.550 – formate-tetrahydrofolate ligase MeSH D08.811.464.259.850 – peptide synthases MeSH D08.811.464.259.850.400 – glutamate-cysteine ligase MeSH D08.811.464.259.850.500 – glutathione synthase

Sources: en.wikipedia.org

Frequently asked questions

Is CJC-1295 a natural hormone?

No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.

Why do two versions share one name?

Early development used the albumin-binding form, and a shorter variant was later discussed under the same label. Because the two differ in half-life and handling, ambiguity arises whenever a source omits the variant designation.

What is the relationship to GRF(1-29)?

The compound derives from that fragment but is not identical to it. The parent fragment lacks the stabilizing substitutions, so its degradation rate and duration of action differ noticeably.

Which receptor does the compound target?

It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.

Network